Recent progress on tyrosine kinase 2 JH2 inhibitors

被引：7

作者：

Deng, Lidan ^{[1
]}

Wan, Li ^{[1
]}

Liao, Tingting ^{[2
]}

Wang, Lin ^{[3
]}

Wang, Jie ^{[4
]}

Wu, Xianbo ^{[1
]}

Shi, Jianyou ^{[1
,5
,6
,7
]}

机构：

[1] Chengdu Sport Univ, Sch Sports Med & Hlth, Chengdu 610041, Sichuan, Peoples R China

[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China

[3] Xihua Univ, Coll Food & Bioengn, Chengdu 610039, Peoples R China

[4] Guizhou Univ Tradit Chinese Med, Guiyang 550002, Guizhou, Peoples R China

[5] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Pharm,Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu 610072, Sichuan, Peoples R China

[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China

[7] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2023年 / 121卷

基金：

中国国家自然科学基金;

关键词：

Tyrosine kinase 2 (TYK2); JH2; inhibitor; Autoimmune diseases; Deucravacitinib; BMS-986202; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PSORIATIC-ARTHRITIS; CLINICAL-FEATURES; JAK INHIBITORS; JANUS KINASES; IMMUNE; MECHANISMS; DISCOVERY; STATS; EPIDEMIOLOGY;

D O I：

10.1016/j.intimp.2023.110434

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFN & alpha;/& beta;), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.

引用

页数：10

共 50 条

[41] Recent progress in ferroptosis: inducers and inhibitors
Du, Yunxi
Guo, Zhong
CELL DEATH DISCOVERY, 2022, 8 (01)
[42] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang
Liwu Fu
ActaPharmaceuticaSinicaB, 2015, 5 (05) : 390 - 401
[43] Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis
El-Miligy, Mostafa M. M.
Abd El Razik, Heba A.
Abu-Serie, Marwa M.
FUTURE MEDICINAL CHEMISTRY, 2017, 9 (15) : 1709 - 1729
[44] Protein tyrosine kinase inhibitors as anticancer agents
Supuran, CT
Scozzafava, A
EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (01) : 35 - 53
[45] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, Lihua
Fu, Liwu
ACTA PHARMACEUTICA SINICA B, 2015, 5 (05) : 390 - 401
[46] Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors
Mou, Yi
Wen, Shuai
Li, Yu-Xiu
Gao, Xin-Xing
Zhang, Xin
Jiang, Zheng-Yu
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 202
[47] Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
Lu, X. -L.
Cao, X.
Liu, X. -Y.
Jiao, B. -H.
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (12) : 1117 - 1124
[48] Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Norman, Peter
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (08) : 891 - 899
[49] Recent Progress of Glutathione Peroxidase 4 Inhibitors in Cancer Therapy
Liu, Shangde
Wang, Jian
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2025, 25 (01) : 42 - 57
[50] Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors
Hoi, Pui Man
Li, Shang
Vong, Chi Teng
Tseng, Hisa Hui Ling
Kwan, Yiu Wa
Lee, Simon Ming-Yuen
METHODS, 2015, 71 : 85 - 91

← 1 2 3 4 5 →